

SERUM FERRITIN and SERUM HEPcidIN LEVELS as PREDICTORS of EARLY POST HEMATOPOIETIC STEM CELL TRANSPLANTATION (<100D) INFECTIONS

Thesis

Submitted for partial fulfillment of the master degree of
In Clinical Haematology

By

Shama Morsy Abd Elaziz Alkazaz
M.B.B.Ch, Faculty of Medicine-Alexandria University

Supervised By

Prof. Dr. Shaza Abd Elwahab Ahmed
Professor of Haematology & BMT
Faculty of Medicine – Ain Shams University

Prof. Dr. Soha Raouf Youssef
Professor of Clinical Pathology
Faculty of Medicine – Ain Shams University

Dr. Rasha Ibrahim Ibrahim
Lecturer of Internal Medicine & Haematology
Faculty of Medicine, Ain shams University

Faculty of Medicine
Ain Shams University
2013

List of Contents

<i>Title</i>	<i>Page No.</i>
List of Abbreviations	ii
List of Tables	v
List of Figures	vi
Introduction	1
Aim of the work.....	3
<u>Review of Literature</u>	
• Overview of Hematopoietic Stem Cell Transplantation	4
• Iron Overload in Hematologic Malignancies and Outcome after Transplantation.....	36
• Iron Overload Post- Hematopoietic Stem Cell Transplantation.....	72
• Serum Ferritin and Serum Hepcidin Before Transplantation and Outcome After Transplant	84
Patients and Methods	93
Results	100
Discussion.....	117
Summary and Conclusions	124
Recommendations	126
References	127
Arabic Summary	--

List of Abbreviations

aGVHD	Acute Graft-versus-host disease
AIHA	Auto immune hemolytic anemia
ALL	Acute lymphoblastic leukemia
AML	Acute myelogenous leukemia
ATG	Antithymocyte globulin
BMP	Bone morphogenic protein
BMT	Bone marrow transplantation
BOOP	Bronchiolitis obliterans organizing pneumonia
BSI	Blood Stream Infection
CMI	Cell mediated immunity
CML	Chronic myelogenous leukemia
CMV	Cytomegalovirus
Dcytb	Duodenal cytoplasmic b-like protein
DFS	Disease free survival
DMT1	Divalent metal transporter 1
EBV	Epstein-Barr virus-related
ECF	Extra cellular fluid
ELISA	Enzyme-linked immunosorbent assay
EPO	Erythropoietin
FDA	Food and Drug Administration
Fe²⁺	Ferrous
Fe³⁺	Ferric
G-CSF	Granulocyte colony stimulating factor
GVHD	Graft-versus-host disease

List of Abbreviations (Cont...)

GVM	Graft-versus-malignancy
GVT	Graft-versus-tumor
HEPA	High-efficiency particulate air
HIF	Hypoxia-inducible factor
HLAs	Human leucocyte antigens
HPLC	High-performance liquid chromatography
HSC	Hematopoietic stem cell
HSCT	Hematopoietic stem cell transplantation
HSV	Herpes simplex virus
IC	Iron chelation
IL-1	Interleukin-1
IL-2	Interleukin-2
IL-6	Interleukin-6
LONIPCs	Late-onset noninfectious pulmonary complications
LPI	Labile plasma iron
MDS	Myelodysplastic syndrome
MHC	Major histocompatibility complex
MMR	Measles mumps rubella
MRI	Magnetic resonance imaging
NTBI	Nontransferrin-bound iron
OS	Overall survival
PC	Pneumocystis carinii
PCR	Polymerase chain reaction
PTLD	Post-transplant lymphoproliferative disorder

List of Abbreviations (Cont...)

PUV	Psoralen plus ultraviolet
RIC	Reduced-intensity conditioning
SOS	Sinusoidal obstruction syndrome
TBI	Total body irradiation
TF	Transferrin
TFR1	Transferrin receptor 1
TGF-β	Transforming growth factor- β
TNF	Tumor necrosis factor
TMP-SMZ	Trimethoprim sulphamethoxazol
TRAP	Total radical antioxidant parameter of plasma
TRM	Transplant-related mortality
TSH	Thyroid-stimulating hormone
VOD	Veno-occlusive disease

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
------------------	--------------	-----------------

Tables of Review:

Table (1):	Characteristics of Various Sources of Stem Cells:	8
Table (2):	Indications for Hematopoietic Stem Cell Transplantation.....	10
Table (3):	Clinical staging of aGVHD by the affected organ systems.	15
Table (4):	The minimal daily iron requirements.	44
Table (5):	Causes of increased NTBI in HSCT recipients.	67
Table (6):	Published guidelines for managing iron overload in HSCT recipients	74

Tables of Results:

Table (1):	Patients' demographic data:	101
Table (2):	Patients' classification by disease entity:	102
Table (3):	Patients' classification according to type of transplant:	103
Table (4):	Laboratory data of patients:.....	104
Table (5):	Clinical data of patients:	105
Table (6):	Comparison between patients and control regarding to serum ferritin level.	106
Table (7):	Comparison between patients and control regarding to serum hepcidin level.	107
Table (8):	Serum ferritin level and episodes of infection.	109
Table (9):	Serum hepcidin level and episodes of infection.	110
Table (10):	Correlation between hepcidin and ferritin & correlation between overall-survival among all cases.	113
Table (11):	Correlation between ferritin and hepcidin in positive culture.....	114
Table (12):	ROC curve for measurement of serum ferritin (ng/ml) with respect to overall survival.....	115
Table (13):	ROC curve between overall survival as regard serum hepcidin (ng/ml).	116

List of Figures

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
<u>Figures of Review:</u>		
Fig. (1):	Hematopoietic and Stromal Stem Cell Differentiation.....	4
Fig. (2):	Pathophysiology of acute GVHD	14
Fig. (3):	Maculopapular disseminated exanthema in aGVHD	16
Fig. (4):	Erythematous macules involving the palms in aGVHD	16
Fig. (5):	Herpes simplex virus after stem cell transplantation.	23
Fig. (6):	Heme synthesis occurs partly in the mitochondria and partly in the cytoplasm.....	37
Fig. (7):	Structure of Heme.	37
Fig. (8):	Distribution of iron in Adults.	39
Fig. (9):	The iron cycle in humans.	41
Fig. (10):	Regulation of the absorption of intestinal iron	48
Fig. (11):	The Transferrin Cycle.....	50
Fig. (12):	Schematic representation of the hepcidin sequence and structure.....	53
Fig. (13):	Regulation of hepcidin expression is a complex phenomenon which may involve multiple factors including	58
Fig. (14):	Hepcidin controls intestinal iron absorption by regulating ferroportin expression on the basolateral membrane of enterocytes.	65
Fig. (15):	Mean \pm SD serum level of the calculated transferrin saturation in 10 allogenic SCT patients during the peritransplantation period.....	68
Fig. (16):	Iron overload in patients undergoing HSCT.....	71
Fig. (17):	Effect of management of iron levels with iron chelation therapy on outcome in pediatric HSCT patients	81

List of Figures (Cont...)

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Figures of Results:		
Fig (1):	Patients' demographic data.....	101
Fig (2):	Patients' classification by disease entity.....	102
Fig (3):	Patients' classification according to type of transplant.....	103
Fig (4):	Clinical data of patients.....	105
Fig. (5):	Boxplot representation of the comparison between patients and control as regards serum ferritin level.	106
Fig. (6):	Boxplot representation of the comparison between patients and control as regards serum hepcidin levels.....	107
Fig. (7):	Incidence of all infectious episodes in patients.	108
Fig. (8):	Boxplot representation of the Serum ferritin level and episodes of infection.	109
Fig. (9):	Boxplot representation of the Serum hepcidin level and episodes of infection.	110
Fig. (10):	Overall survival before 100 days.	111
Fig. (11):	Causes of death before 100 days.....	112
Fig. (12):	Positive Correlation between hepcidin and ferritin in all cases.	114
Fig. (13):	ROC curve between overall survival as regard S. Ferritin (ng/ml).....	115
Fig. (14):	ROC curve between overall survival as regard serum hepcidin (ng/ml).	116

INTRODUCTION

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become a curative treatment for hematologic malignancies. Although improvement of outcome has been achieved in recent decades by progress in various procedures such as the prevention of graft-versus-host disease (GVHD), infectious complications remain an important contributor to transplant-related mortality (*Bjorklund et al., 2007*).

Iron overload is common in patients undergoing hematopoietic stem cell transplantation (HSCT) for hematologic disorders (*Altes et al., 2004*).

A recently accumulated body of evidence suggests that iron overload is associated with adverse clinical outcomes in HSCT (*Altes et al., 2009*).

Other studies have shown that pretransplant iron overload in autologous or allogeneic HSCT was a risk factor associated with post transplant complications, such as mucositis, bacterial, and fungal infection, and hepatic veno-occlusive disease (VOD) (*Kataoka et al., 2009*).

High pretransplant serum ferritin level was strongly associated with lower overall and disease free survival (OS, DFS) in patients with allogeneic HSCT that was performed as a treatment for acute leukemia and myelodysplastic syndrome (MDS) (*Armand et al., 2007*).

Pretransplant serum ferritin level was a risk factor for the occurrence of BSI (Blood Stream Infection) within 100 days after allo-HSCT (*Tachibana et al., 2010*).

Hepcidin, first identified in human blood and urine as an antimicrobial small peptide, is now considered to be a central molecule that regulates iron metabolism (*Park et al., 2001*).

Hepcidin decreases iron absorption from the intestine and blocks its release from iron stores by down regulating the expression of the cellular iron exporter, ferroportin. Therefore, it is hypothesized that serum hepcidin level could be a useful predictor of iron overload and inflammatory condition prior to HSCT (*Ganz et al., 2005*).

Consistent association of high hepcidin levels with high risk for developing bacterial infection were observed when analyses were confined to either the low-or high-ferritin subgroups. These finding collectively suggest that hepcidin can be used as better predictor of documented bacterial infection than serum ferritin level (*Murphy et al., 2007*).

AIM OF THE WORK

Was to compare between pretransplant serum ferritin and serum hepcidin levels as predictors of early (before 100 days) post HSCT infections.

Chapter (1)

OVERVIEW OF HEMATOPOIETIC STEM CELL TRANSPLANTATION

What Is a Hematopoietic Stem Cell?

A hematopoietic stem cell is a cell isolated from the blood or bone marrow that can renew itself, can differentiate to a variety of specialized cells, can mobilize out of the bone marrow into circulating blood, and can undergo programmed cell death, called apoptosis-a process by which cells that are detrimental or unneeded self-destruct (*Sharp et al., 2000*).




Fig. (1): Hematopoietic and Stromal Stem Cell Differentiation (*Terai et al., 2005*).

Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually

derived from bone marrow, peripheral blood, or umbilical cord blood. Hematopoietic stem cell transplantation remains a risky procedure with many possible complications; it has traditionally been reserved for patients with life-threatening diseases. While occasionally used experimentally in nonmalignant and nonhematologic indications such as severe disabling auto-immune disease and cardiovascular disease, the risk of fatal complications appears too high to gain wider acceptance (*Tyndall et al., 2000*).

Georges Mathé, a French oncologist, performed the first bone marrow transplant in 1959 on five Yugoslavian nuclear workers whose own marrow had been damaged by irradiation caused by a Criticality accident at the Vinča Nuclear Institute, but all of these transplants were rejected. Mathé later pioneered the use of bone marrow transplants in the treatment of leukemia (*Burt et al., 2008*).

Types of stem cell transplantation:

Types of hematopoietic stem cell transplantation (HSCT) are typically categorized based on the source of progenitor cells used in the transplant. These cells have 3 main sources: the patient (an autologous transplant), someone besides the patient (an allogeneic transplant), or donated umbilical cord blood (a cord blood or umbilical cord blood transplant). Each of these sources of cells has specific advantages and disadvantages, and each has found particular applications in the care of patients with oncologic or immunologic disorders (*Jonathan, 2011*).

Autologous

Autologous transplantation is typically used as a method of returning the patient's own stem cells as a rescue therapy after high-dose myeloablative therapy. This is generally used in chemo sensitive hematopoietic and solid tumors to eliminate malignant cells by administering higher-dose chemotherapy than could normally be tolerated by the bone marrow of the patient, with the target of increasing the chances of killing remaining tumor cells. The high dose chemotherapy is then followed with subsequent rescue of the host's bone marrow with previously collected autologous stem cells. Immunosuppression is not required after autologous transplantation because the immune system that is reconstituted is that of the original host. Because the native immune system returns after autologous transplant, this technique is not used for correction of immunodeficiencies (*Jonathan 2011*).

Allogeneic

Allogeneic transplantation refers to the use of stem cells from a donor source other than the subject. The source of donated stem cells (the donor) may be genetically related or unrelated to the recipient. This type of transplant is used in the context of many malignant and nonmalignant disorders to replace a defective host marrow or immune system with a normal donor marrow and immune system. The degree of HLA match between the donor and the recipient is perhaps the most important factor in these transplants; well-matched transplants

decrease risks of graft rejection and graft versus host disease (GVHD), both of which are among the most serious sequelae of transplantation (*Jonathan 2011*).

Cord blood transplantation refers to the use of hematopoietic stem cells collected from the umbilical cord and placenta. The use of cord blood transplantation has rapidly increased because of several favorable factors, including ease of collection, expanded and prompt availability, no risk to the donors, a decreased risk of adverse effects (eg, GVHD, transmission of infections), and increased tolerance to HLA-mismatch (*Koh et al.,2004*).

Use of cord blood as a source of donor stem cells can be limited by the quantity of cells available in a typical sample. Improved collection techniques have increased the size of aliquots available from a given donor and are making this source available to more patients. Additional research is exploring the use of multiple cord blood transplants, in which multiple cord blood donors are used during the same transplantation procedure to improve engraftment times (*Lister et al.,2007*).

In November 2011, the US Food and Drug Administration (FDA) approved the first umbilical cord blood product for use in stem cell transplantation. The product contains hematopoietic progenitor cells from human cord blood (HemaCord, New York Blood Center)(*FDA, 2011*).